Today we sit down with Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada and with Dr. Nathan Cherny of Shaare Zedek Medical Center in Jerusalem, Israel to talk about the European Society of Medical Oncology (ESMO) and the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS), which aims to improve cancer therapy decision-making. 

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.80 ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) with Drs. Bishal Gyawali and Nathan Cherny

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.80 ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) with Drs. Bishal Gyawali and Nathan Cherny

Download our free app to listen on your phone